NRXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NRX Pharmaceuticals Inc (NRXP) is not a strong buy for a beginner, long-term investor at this time. Despite a positive analyst rating and a potential FDA pathway for its product, the company's financial performance is weak, with significant drops in net income and EPS. Technical indicators suggest a neutral trend, and there are no significant trading signals or recent news catalysts to support immediate action. The options data reflects low put-call ratios, indicating bullish sentiment, but this is not sufficient to justify a buy recommendation given the overall data.
The MACD is positive and expanding, indicating a slight bullish trend. However, the RSI is neutral at 78.797, and moving averages are converging, suggesting no clear directional momentum. The stock is trading near its resistance level (R1: 2.538), which may limit upside potential in the short term.
This de-risks the program and increases valuation potential.
Weak financial performance in Q4 2025, with a 103.97% drop in net income and a 101.35% drop in EPS. No recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q4 2025, revenue remained flat at $983,000 YoY. Net income dropped significantly to $360,000 (-103.97% YoY), and EPS fell to 0.01 (-101.35% YoY). Gross margin remained stable at 54.22%.
H.C. Wainwright maintains a Buy rating and increased the price target to $45 from $40, supported by a clear FDA pathway and expanded valuation for NRX-100.
